Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Altered Hepatic Transport by Fetal Arsenite Exposure in Diet-Induced Fatty Liver Disease.

Authors: Ditzel, Eric J; Li, Hui; Foy, Caroline E; Perrera, Alec B; Parker, Patricia; Renquist, Benjamin J; Cherrington, Nathan J; Camenisch, Todd D

Published In J Biochem Mol Toxicol, (2016 Jul)

Abstract: Non-alcoholic fatty liver disease can result in changes to drug metabolism and disposition potentiating adverse drug reactions. Furthermore, arsenite exposure during development compounds the severity of diet-induced fatty liver disease. This study examines the effects of arsenite potentiated diet-induced fatty liver disease on hepatic transport in male mice. Changes were detected for Mrp2/3/4 hepatic transporter gene expression as well as for Oatp1a4/2b1/1b2. Plasma concentrations of Mrp and Oatp substrates were increased in arsenic exposure groups compared with diet-only controls. In addition, murine embryonic hepatocytes and adult primary hepatocytes show significantly altered transporter expression after exposure to arsenite alone: a previously unreported phenomenon. These data indicate that developmental exposure to arsenite leads to changes in hepatic transport which could increase the risk for ADRs during fatty liver disease.

PubMed ID: 26890134 Exiting the NIEHS site

MeSH Terms: Angiogenic Proteins/genetics; Angiogenic Proteins/metabolism; Animals; Arsenites/toxicity*; Biological Transport/drug effects; Diet, High-Fat/adverse effects*; Embryo, Mammalian; Female; Fetus; Gene Expression Regulation/drug effects*; Hepatocytes/drug effects*; Hepatocytes/metabolism; Hepatocytes/pathology; Liver-Specific Organic Anion Transporter 1; Liver/drug effects*; Liver/metabolism; Liver/pathology; Male; Mice; Multidrug Resistance-Associated Proteins/genetics; Multidrug Resistance-Associated Proteins/metabolism; Non-alcoholic Fatty Liver Disease/etiology; Non-alcoholic Fatty Liver Disease/genetics; Non-alcoholic Fatty Liver Disease/metabolism*; Non-alcoholic Fatty Liver Disease/pathology; Organic Anion Transporters, Sodium-Independent/genetics; Organic Anion Transporters, Sodium-Independent/metabolism; Organic Cation Transport Proteins/genetics; Organic Cation Transport Proteins/metabolism; Pregnancy; Primary Cell Culture; Signal Transduction

Back
to Top